Tandem Biomolecular Drug System
A First-in-Class Precision Oncology Platform
A cancer-selective ligand guides TBDS to tumor cells overexpressing surface receptors, sparing healthy tissue.
Upon binding, the lytic peptide disrupts lipid bilayer integrity — physically puncturing the cancer cell membrane.
Because TBDS acts through a physical, non-metabolic mechanism, cancer cells cannot develop resistance through efflux pumps or target mutation.
The targeting and lytic domains are independently interchangeable — enabling rapid adaptation across multiple tumor types and indications.
We're actively engaging investors, pharma partners, and research collaborators. Contact us to request data packages or schedule a conversation with the team.